Julia Kaiser1, Cornelia Kronberger2, Angelika Moder3, Peter Kopp1, Markus Wallner1, Roland Reitsamer4, Thorsten Fischer4, Christoph Fussl1, Franz Zehentmayr1, Felix Sedlmayer1, Gerd Fastner5. 1. Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. 2. Institute of Pathology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. 3. Institute of Inborn Errors in Metabolism, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. 4. Department of Gynecology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. 5. Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. Electronic address: g.fastner@salk.at.
Abstract
PURPOSE: To assess retrospectively the role of an anticipated intraoperative tumor electron radiation therapy (IOERT) as a bed boost during breast-conserving surgery followed by conventional whole breast irradiation (WBI). METHODS AND MATERIALS: An unselected cohort of 770 breast cancer patients of all risk types was analyzed in terms of local control (LC) and survival outcome. Patients were treated by breast-conserving surgery, IOERT of 10 Gy, and WBI to total median doses of 54 Gy (range, 1.6-2). Patients were retrospectively analyzed for LC, locoregional control, metastasis-free survival (MFS), overall survival (OS), and breast cancer-specific survival (BCSS). RESULTS: After a median follow-up of 121 months (range, 4-200), 21 (2.7%) in-breast recurrences (IBRs) were observed, 107 patients (14%) died and 106 (14%) developed metastases. Ten-year rates of LC, locoregional control, MFS, OS, and BCSS amounted to 97.2%, 96.5%, 86%, 85.7%, and 93.2 %, respectively. In multivariate analysis, HER2+ and triple-negative breast cancer subtype (TN) turned out to be significant negative predictors for IBRs (hazard ratios, 15.02 and 12.87, respectively; P < .05). Sorted by subtypes, 10-year LC rates were observed in 98.7% (range, 96.7%-99.5%) (luminal A), 98% (range, 94%-99.3%) (luminal B), 87.9% (range, 66.2%-96%) (HER2+), and 89% (range, 76.9%-94.9%) (TN), respectively. CONCLUSIONS: After 10 years, boost IOERT maintains high LC rates in any risk setting.
PURPOSE: To assess retrospectively the role of an anticipated intraoperative tumor electron radiation therapy (IOERT) as a bed boost during breast-conserving surgery followed by conventional whole breast irradiation (WBI). METHODS AND MATERIALS: An unselected cohort of 770 breast cancerpatients of all risk types was analyzed in terms of local control (LC) and survival outcome. Patients were treated by breast-conserving surgery, IOERT of 10 Gy, and WBI to total median doses of 54 Gy (range, 1.6-2). Patients were retrospectively analyzed for LC, locoregional control, metastasis-free survival (MFS), overall survival (OS), and breast cancer-specific survival (BCSS). RESULTS: After a median follow-up of 121 months (range, 4-200), 21 (2.7%) in-breast recurrences (IBRs) were observed, 107 patients (14%) died and 106 (14%) developed metastases. Ten-year rates of LC, locoregional control, MFS, OS, and BCSS amounted to 97.2%, 96.5%, 86%, 85.7%, and 93.2 %, respectively. In multivariate analysis, HER2+ and triple-negative breast cancer subtype (TN) turned out to be significant negative predictors for IBRs (hazard ratios, 15.02 and 12.87, respectively; P < .05). Sorted by subtypes, 10-year LC rates were observed in 98.7% (range, 96.7%-99.5%) (luminal A), 98% (range, 94%-99.3%) (luminal B), 87.9% (range, 66.2%-96%) (HER2+), and 89% (range, 76.9%-94.9%) (TN), respectively. CONCLUSIONS: After 10 years, boost IOERT maintains high LC rates in any risk setting.
Authors: G Oses; C Cases; I Valduvieco; B Farrús; I Alonso; X Caparrós; J Mases; D Muñoz-Guglielmetti; A Biete; C Castro; E Escudero; M Molina; A Herreros; J Saez; M Mollà Journal: Clin Transl Oncol Date: 2021-02-03 Impact factor: 3.405
Authors: X Li; J Sanz; N Argudo; M Vernet-Tomas; N Rodríguez; L Torrent; E Fernández-Velilla; O Pera; Y Huang; P Nicolau; M Jiménez; M Segura; M Algara Journal: Clin Transl Oncol Date: 2021-11-18 Impact factor: 3.405
Authors: Katarzyna Kulcenty; Igor Piotrowski; Joanna Patrycja Wróblewska; Janusz Wasiewicz; And Wiktoria Maria Suchorska Journal: Cancers (Basel) Date: 2019-12-18 Impact factor: 6.639